Darapladib

Drug Profile

Darapladib

Alternative Names: 480848; SB-480848

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; Human Genome Sciences
  • Developer GlaxoSmithKline
  • Class Acetamides; Fluorobenzenes; Pyrimidinones; Small molecules; Sulfides
  • Mechanism of Action 1-alkyl-2-acetylglycerophosphocholine esterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Atherosclerosis; Diabetic macular oedema

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 12 Nov 2016 Adverse events data from the phase III SOLID-TIMI 52 trial in Atherosclerosis presented at the 89th Annual Scientific Sessions of the American Heart Association
  • 01 Aug 2014 GlaxoSmithKline completes a phase I pharmacodynamic trial in Atherosclerosis (in patients with Type-2 diabetes mellitus) in United Kingdom (NCT02058641)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top